Neeraj Agarwal, MD, FASCO

Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert

A profound honor – this generous gift by Toby Shor is a tribute to bladder cancer patients, the care that makes survivorship possible, and the remarkable team I’m privileged to work with. @MDAndersonNews #OncSurgery @NNavai @KKBree @DrByronLee @OAlhalabiMD @DocMattCampbell…

A warm invite to all of our GU Colleagues to attend IN PERSON OR ONLINE (HYBRID) To the International Urology Cancer Summit🇬🇧 in Portsmouth!! REGISTER HERE👉 buff.ly/ahAjiFj The International Urology Cancer Summit is a free, independent educational event for all…

Could not think of a better person to take on this tremendous role for this @AmericanCancer journal! Congrats @DrRanaMcKay! @DrChoueiri @BradMcG04 @shilpaonc @VivekSubbiah @neerajaiims @PGrivasMDPhD

All #KCRS25 session recordings are now available in the Attendee Hub for registrants—your early access is live! Didn’t register this year? No worries. Recordings will be posted soon at kcrs.kidneycan.org. Stay tuned! #AcceleratingCures

Following the standard of care won't get the job done against cancer. @montypal and @DrEdKim, physician-in-chief @cityofhopeoc, discuss why in the latest “On the Edge of Breakthrough: Voices of Cancer Research” #podcast episode. Listen: spoti.fi/4hOfEJV

The Post-ASCO 2025 GU Cancer Highlights virtual webinar by @VJOncology WATCH NOW On Demand 👉 bit.ly/3UmZI7Q Featuring expert presentations and discussions on key GU cancer abstracts from ASCO 2025. @neerajaiims @ERPlimackMD @AndreaNecchi

STAMPEDE: ADT leads to high fracture rates in prostate cancer, esp. with mets. Zoledronic acid lowers fracture risk in metastatic, not non-metastatic. Should we add ZA or Deno in bone protecting dose? #prostatecancer #Oncology @Annals_Oncology @APCCC_Lugano @OncoAlert…

@LouiseEmmett giving updates of #ENZAP & #EVOLUTION trials — such important IITs to help us understand ideal use of 177Lu-PSMA in met #prostatecancer. Congrats to all within @ANZUPtrials who contributed to these trials! #ANZUP25

In high-risk prostate cancer, radiotherapy plus ADT significantly reduces the risk of distant metastasis compared to surgery-based approaches. However, post-metastasis survival does not differ between treatments. @EurUrolOncol @DrSpratticus @OncoAlert @APCCC_Lugano @Uroweb…

Age of “OMICs” @NeuroCellPress @OncoAlert cell.com/neuron/fulltex…

🧬 TWEETORIAL/X'torial: Why Every Rare Cancer Patient Deserves Molecular Profiling 🧬 1/15 🚨 Here's a shocking fact: Rare cancers make up 25% of ALL cancer cases, yet most patients never get the molecular testing that could save their lives. 👉In our policy & practice paper -…

Great kickoff to clinical trials workshop #ANZUP25 — @mlemesurier w patient perspective and @ChrisGianacas biostats on collaborative efforts for clinical trials. Same global themes for clinical trial development. @ANZUPtrials @DrCraigGedye @Prof_IanD

Behind every data point is a story. Every bar, every dot, represents a patient. Let’s never forget the human side of science. #KCRS25 #KidneyCancer @OncoAlert @kidneycan @urotoday @ASCO @DrChoueiri @advocatekidneys @IKCCorg @Uromigos

A very informative and detailed discussion on practice changing data and trial updates in bladder cancer by @PGrivasMDPhD #BestOfASCO 2025 in Boise! education.binaytara.org/content/best-a…

We’re proud to present the KidneyCAN Catalyst Award to Dr. Rana McKay of UC San Diego. Dr. McKay is a leader whose work has helped move the field of kidney cancer forward through groundbreaking research, clinical collaboration, and a deep commitment to patients and advocacy. Her…

That's a wrap on #KCRS25! Thank you to everyone who joined us, whether you were with us in Boston or tuning in virtually from around the world. Your presence, questions, and passion for collaboration made this year’s summit one to remember. Until next time, keep pushing the…

Celebrating the winners of the KCRS25 Merit Awards for Clinical Research! 👏 Dr. Yu-wei Chen, University of California San Diego 👏 Dr. Koral Shah, City of Hope 👏 Ruchi Agarwal, University of Pennsylvania #KCRS25 #AcceleratingCures

Amazing to see 2 simultaneous practice-changing pubs in @TheLancet showing efficacy of Enza+Tala in mCRPC - all comers, HRR+ and BRCA+. Proud to have been involved @PeterMacCC @gu_onc . Great leadership from #KarimFizazi & @neerajaiims

Real-world treatment patterns in #mHSPC in the US. @umangtalking and @neerajaiims @huntsmancancer discuss encouraging findings from a large retrospective study using the Flatiron Health database of 14,000 patients showing that ADT intensification therapies have risen dramatically…